Related Experiment Video
Updated: Apr 21, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
(E)-Labda dial-Loaded Nanoparticles for Triple Negative Breast Cancer
Anum Munir1,2, Muhammad Rizwan3, Alan Janbey2
1Division of Natural Sciences, University of Kent, Canterbury, Kent, England.
Introduction:
Triple-negative breast cancer (TNBC) is the most aggressive kind of breast cancer, with no hormone receptors and resistance to targeted therapy. Chemotherapy is the current standard; however, it is limited by toxicity, poor response, and high recurrence, emphasising the need for innovative methods.
Methods:
This study investigates the therapeutic potential of (E)-labda-8(17), 12-diene-15,16-dial ((E)-labda dial), a bioactive chemical found in Curcuma amada (mango ginger) that was formulated into nanoparticles to increase transport and effectiveness. Whole-genome sequencing of TNBC cell lines was used to detect protein-altering mutations, which were then assessed using molecular docking and dynamics simulations to assess (E)-labda dial interactions with key mutant proteins (BRCA1, BRCA2, BARD1, PALB2, TP53, CHEK2). Lipid-based nanoparticles (LNPs) and polymeric nanoparticles (PNPs) were developed and tested for drug encapsulation, release kinetics, and stability. MTT and other functional tests were used to assess cytotoxic effects, and in silico pharmacokinetic models were carried out to anticipate treatment results.
Results:
Results showed that PNPs outperformed LNPs in terms of encapsulation efficiency, sustained drug release, and tumour inhibition. Docking investigations demonstrated that mutant CHEK2, BARD1, and PALB2 bind to (E)-labda dial more strongly, indicating that carcinogenic pathways may be disrupted.
Discussion:
These data, taken together, emphasise the abilities of (E)-labda dial-loaded nanoparticles as a targeted treatment method for TNBC, with potential effectiveness and toxicity benefits over traditional chemotherapy.
Conclusion:
This work lays the basis for precision and personalised treatment for TNBC patients. However, future optimisation and clinical validation of these nanoparticles can be done in future to determine their translational potential for use in practice.
Insights
This study explores (E)-labda dial-loaded nanoparticles as a novel treatment for triple-negative breast cancer (TNBC). Polymeric nanoparticles show promise for enhanced TNBC therapy, offering potential benefits over traditional chemotherapy.
Area of Science:
- Biochemistry and Nanotechnology
- Cancer Research
- Pharmacology
Background:
- Triple-negative breast cancer (TNBC) is aggressive, lacking hormone receptors and targeted therapy options.
- Current chemotherapy for TNBC has limitations including toxicity, poor response rates, and high recurrence.
- There is a critical need for innovative and more effective therapeutic strategies for TNBC.
Purpose of the Study:
- To investigate the therapeutic potential of (E)-labda dial, a natural compound from Curcuma amada, formulated into nanoparticles for TNBC treatment.
- To evaluate the efficacy and safety of (E)-labda dial-loaded nanoparticles compared to traditional chemotherapy.
- To explore the interaction of (E)-labda dial with key mutant proteins in TNBC.
Main Methods:
- Whole-genome sequencing identified TNBC mutations; molecular docking and dynamics simulations assessed (E)-labda dial interactions with mutant proteins (BRCA1, BRCA2, BARD1, PALB2, TP53, CHEK2).
- Lipid-based nanoparticles (LNPs) and polymeric nanoparticles (PNPs) were developed, characterized for drug encapsulation, release kinetics, and stability.
- Cytotoxic effects were evaluated using MTT assays, and in silico pharmacokinetic models predicted treatment outcomes.
Main Results:
- Polymeric nanoparticles (PNPs) demonstrated superior encapsulation efficiency, sustained drug release, and tumor inhibition compared to LNPs.
- Molecular docking revealed stronger binding of (E)-labda dial to mutant CHEK2, BARD1, and PALB2, suggesting disruption of carcinogenic pathways.
- (E)-labda dial-loaded nanoparticles showed potential for targeted TNBC treatment with improved efficacy and reduced toxicity.
Conclusions:
- Nanoparticle formulations of (E)-labda dial represent a promising targeted therapy for TNBC, potentially overcoming limitations of conventional chemotherapy.
- This research provides a foundation for personalized and precision medicine approaches in TNBC treatment.
- Further optimization and clinical validation are necessary to establish the translational potential of these nanoparticles in practice.
